HomeCompareHLTRF vs O

HLTRF vs O: Dividend Comparison 2026

HLTRF yields 66.67% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 O wins by $759.00 in total portfolio value· pulled ahead in Year 10
10 years
HLTRF
HLTRF
● Live price
66.67%
Share price
$3.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33.5K
Annual income
$11.08
Full HLTRF calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — HLTRF vs O

📍 O pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHLTRFO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HLTRF + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HLTRF pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HLTRF
Annual income on $10K today (after 15% tax)
$5,666.67/yr
After 10yr DRIP, annual income (after tax)
$9.42/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, O beats the other by $4,327.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HLTRF + O for your $10,000?

HLTRF: 50%O: 50%
100% O50/50100% HLTRF
Portfolio after 10yr
$33.9K
Annual income
$2,556.91/yr
Blended yield
7.55%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

HLTRF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
-1.0
Piotroski
5/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HLTRF buys
0
O buys
0
No recent congressional trades found for HLTRF or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHLTRFO
Forward yield66.67%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%15.1%
Portfolio after 10y$33.5K$34.2K
Annual income after 10y$11.08$5,102.74
Total dividends collected$8.1K$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusHoldHold

Year-by-year: HLTRF vs O ($10,000, DRIP)

YearHLTRF PortfolioHLTRF Income/yrO PortfolioO Income/yrGap
1$14,033$3,333.33$10,818$608.16+$3.2KHLTRF
2$17,202$2,185.88$11,787$741.68+$5.4KHLTRF
3$19,658$1,252.04$12,946$911.00+$6.7KHLTRF
4$21,702$668.61$14,345$1,127.94+$7.4KHLTRF
5$23,566$344.93$16,056$1,409.05+$7.5KHLTRF
6$25,391$175.03$18,171$1,777.83+$7.2KHLTRF
7$27,257$88.12$20,820$2,268.21+$6.4KHLTRF
8$29,209$44.20$24,188$2,929.90+$5.0KHLTRF
9$31,276$22.14$28,533$3,837.11+$2.7KHLTRF
10← crossover$33,476$11.08$34,235$5,102.74$759.00O

HLTRF vs O: Complete Analysis 2026

HLTRFStock

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.

Full HLTRF Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this HLTRF vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HLTRF vs SCHDHLTRF vs JEPIHLTRF vs KOHLTRF vs MAINHLTRF vs STAGHLTRF vs ADCHLTRF vs NNNHLTRF vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.